Welcome to our dedicated page for Nuvasive news (Ticker: NUVA), a resource for investors and traders seeking the latest updates and insights on Nuvasive stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Nuvasive's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Nuvasive's position in the market.
NuVasive, Inc. (NASDAQ: NUVA) has launched Modulus® ALIF, a 3D-printed porous titanium implant designed for anterior lumbar interbody fusion. This innovative technology aims to enhance osseointegration and improve surgical outcomes. The implant features a proprietary design, zero-step locking mechanism, and versatile instrumentation for various patient anatomies. Positive feedback from surgeons highlights its potential in achieving better fusion results. NuVasive will showcase Modulus ALIF at industry events, reinforcing its commitment to spine surgery innovation.
NuVasive (NASDAQ: NUVA) announced it will release its second quarter 2021 earnings results on July 28, 2021, after market close. A conference call will follow at 4:30 p.m. ET to discuss financial performance. The call can be accessed via dial-in or through a live webcast on the company's Investor Relations page. NuVasive, a leader in spine technology, focuses on minimally disruptive surgical solutions and has over $1 billion in net sales and approximately 2,700 employees globally.
NuVasive (NASDAQ: NUVA) announced CE Mark approval for its Pulse® platform, marking a significant step in commercialization. This approval allows clinical evaluations in multiple European countries ahead of a global launch planned for later this summer. The Pulse platform integrates various surgical technologies to enhance safety and efficiency in spine surgery. NuVasive aims to leverage this technology in all spine procedures, with demonstrations scheduled at industry events in July 2021.
NuVasive, Inc. (NASDAQ: NUVA) has appointed Daniel J. Wolterman as the independent chair of its Board of Directors, effective immediately. This change follows the retirement of Gregory T. Lucier on May 18, 2021. Wolterman, who joined the Board in July 2015 and has held the position of lead independent director since May 2020, brings nearly 40 years of healthcare experience, including 14 years as CEO of Memorial Hermann Health System. His leadership is expected to support NuVasive's strategy to transform spine surgery and enhance shareholder value.
NuVasive (NASDAQ: NUVA) announced the appointment of Juliet C. Cunningham as vice president of Investor Relations, effective immediately. With over 25 years of experience, Cunningham previously held the same role at Illumina and has extensive experience in investor relations at companies like QUALCOMM. Her role will focus on enhancing the investor relations program and engaging with the investment community. CFO Matt Harbaugh expressed confidence in her ability to drive the company’s long-term strategy as NuVasive aims to transform spine surgery through innovative solutions.
NuVasive reported a 4.4% increase in net sales for Q1 2021, totaling $271.2 million, with a GAAP operating margin of 4.5% and a non-GAAP operating margin of 13.0%. The company experienced a GAAP loss of $7.5 million or $0.15 per share compared to a profit of $5.3 million a year earlier. International sales grew in the low double digits, aided by a recovery in elective surgeries post-COVID-19. The acquisition of Simplify Medical received positive feedback, contributing to strong innovation in spine technology.
NuVasive (NASDAQ: NUVA), a leader in spine technology innovation, announced its participation in two upcoming virtual investor conferences. The Bank of America Securities 2021 Virtual Healthcare Conference is scheduled for May 13, 2021, at 11:00 a.m. ET, while the 2021 Canaccord Genuity Virtual Musculoskeletal Conference will take place on May 20, 2021, at 11:30 a.m. ET. Investors can access the live webcast via the Company’s website, with a replay available for 30 days post-event. NuVasive generates over $1 billion in net sales and operates globally, serving spine surgeons and hospitals.
NuVasive, Inc. (NASDAQ: NUVA) announced it will release its first quarter 2021 earnings on May 5, 2021, post-market. A conference call scheduled for the same day at 4:30 p.m. ET will discuss financial results. Interested parties can access the call via dial-in or live webcast on NuVasive's Investor Relations page. The call will be available for replay until June 5, 2021. NuVasive specializes in innovative spine technology, achieving over $1 billion in net sales, and operates in over 50 countries.
NuVasive, Inc. (NASDAQ: NUVA) announced FDA approval for its Simplify® Cervical Artificial Disc for two-level cervical total disc replacement (cTDR). This landmark approval enhances the growing NuVasive C360 portfolio and signifies strong market potential due to its clinical superiority over traditional anterior cervical discectomy and fusion (ACDF) procedures, with nearly 10% higher overall success rates noted. The Simplify Disc’s innovative design promotes improved patient outcomes and is set to be showcased at the upcoming ISASS Annual Conference.
NuVasive, Inc. (NASDAQ: NUVA) announced the retirement of Gregory T. Lucier from its Board of Directors, effective May 18, 2021. Lucier, who has been with the company since December 2013 and served as CEO from May 2015 to November 2018, played a crucial role in driving NuVasive’s growth to over $1 billion in net sales. His leadership fostered innovation and expansion in spine technology. The company acknowledges Lucier's contributions while expressing confidence in its current leadership to continue advancing its mission and strategies.